长春高新GenSci142胶囊注册临床试验申请获批

Group 1 - The core announcement is that Changchun Gaoxin's subsidiary, Changchun Jinsai Pharmaceutical Co., has received approval from the National Medical Products Administration for the clinical trial of GenSci142 capsules [2][3] - GenSci142 capsules are classified as a Class 1 innovative biological product intended for the treatment of bacterial vaginosis [3] - This approval marks the first clinical trial application for a new drug granted under the recently introduced "30-day channel" for the review and approval of innovative drug clinical trials by the National Medical Products Administration [3]